
Enormous asteroid bigger than a 15-story building headed toward Earth in just DAYS
NASA has announced that asteroid 2025 OW is expected to pass within 393,000 miles of Earth on Monday, July 28.
It's actually one of five asteroids NASA's Jet Propulsion Laboratory (JPL) making a close pass by Earth over the next week.
Two other asteroids, both between 100 and 200 feet long, are projected to miss Earth by more than a million miles on Thursday. Another small asteroid is expected to pass our planet on Saturday.
However, 2025 OW is the largest of this ominous group and will also come much closer to striking the planet on Monday.
The space rock has been measured to be approximately 210 feet long, making it comparable to a 15-story building or a large airplane.
Its projected distance of 393,000 miles would put it just beyond the moon, which orbits Earth 239,000 miles away.
While NASA has said that 2025 OW poses no risk at this time, they noted asteroids of this size could cause minor structural damage or shatter windows if it were to enter the atmosphere over a populated area.
Astronomers categorize 2025 OW as a small to medium-sized asteroid, meaning it's not a 'planet-killer' which would cause an extinction-level event on Earth.
This type of asteroid generally explodes in the atmosphere and doesn't reach the Earth's surface due to the intense frictional heating and pressure placed on the rock as it enters at high speeds.
Scientists said 2025 OW is traveling at about 47,000 miles per hour, which is about an average speed for a near-Earth asteroid (NEA).
For comparison, the 500-foot asteroid 2024 MK was traveling at roughly 34,000 mph when it came within 184,000 miles of Earth last July.
Meanwhile, the worryingly large, 1,100-foot 99942 Apophis is traveling at 67,000 mph and is expected to come within 20,000 miles of Earth on April 13, 2029.
At just 210 feet in length, it won't be visible with the naked eye or through binoculars when it reaches its closest point from the Earth.
When it comes to tracking potentially dangerous asteroids, NASA's calculations are typically right on the money, meaning a major error that brings 2025 OW on a collision course with us unlikely.
NASA JPL's Center for Near-Earth Object Studies (CNEOS) uses ground-based telescopes and planetary radar systems like the Goldstone Solar System Radar to detect and track asteroids. These systems measure an asteroid's position, velocity, and brightness to determine its orbit and size.
While NASA is staying on top of these smaller asteroids in view, scientists have recently raised alarm about dangerous objects coming at our planet from our stellar 'blind side.'
A recent study warned that Venus blocks out our view of many near-Earth asteroids - large space rocks that cross or come near Earth's orbit - setting up the potential for a devastating impact no one sees coming.
Researchers from Brazil, France, and Italy found that several asteroids in sync with Venus's orbit are extremely hard to spot because they're often hidden by the sun's glare.
Three in particular, 2020 SB, 524522, and 2020 CL1, have orbits that take these asteroids dangerously close to Earth.
The three asteroids flying along with Venus measure between 330 and 1,300 feet in diameter, making each one capable of leveling entire cities and setting off massive fires and tsunamis.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
5 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.


The Independent
8 hours ago
- The Independent
‘Fantastic Four: First Steps' scores Marvel's first $100 million box office opening of 2025
Marvel's first family has finally found box office gold. 'The Fantastic Four: First Steps,' the first film about the superheroes made under the guidance of Kevin Feige and the Walt Disney Co., earned $118 million in its first weekend in 4,125 North American theaters, according to studio estimates Sunday. That makes it the fourth biggest opening of the year, behind 'A Minecraft Movie,' 'Lilo & Stitch' and 'Superman,' and the biggest Marvel opening since 'Deadpool & Wolverine' grossed $211 million out of the gate last summer. Internationally, 'Fantastic Four' made $100 million from 52 territories, adding up to a $218 million worldwide debut. The numbers were within the range the studio was expecting. The film arrived in the wake of another big superhero reboot, James Gunn's 'Superman,' which opened three weekends ago and has already crossed $500 million globally. That film, from the other main player in comic book films, DC Studios, took second place with $24.9 million domestically. 'First Steps' is the latest attempt at bringing the superhuman family to the big screen, following lackluster performances for other versions. The film, based on the original Marvel comics, is set during the 1960s in a retro-futuristic world led by the Fantastic Four, a family of astronauts-turned-superhuman from exposure to cosmic rays during a space mission. The family is made up of Reed Richards (Pedro Pascal), who can stretch his body to incredible lengths; Sue Storm (Vanessa Kirby), who can render herself invisible; Johnny Storm (Joseph Quinn), who transforms into a fiery human torch; and Ben Grimm (Ebon Moss-Bachrach), who possesses tremendous superhuman strength with his stone-like flesh. The movie takes place four years after the family gained powers, during which Reed's inventions have transformed technology, and Sue's diplomacy has led to global peace. Both audiences and critics responded positively to the film, which currently has an 88% on Rotten Tomatoes and promising exit poll responses from opening weekend ticket buyers. An estimated 46% of audiences chose to see it on premium screens, including IMAX and other large formats. The once towering Marvel is working to rebuild audience enthusiasm for its films and characters. Its two previous offerings this year did not reach the cosmic box office heights of 'Deadpool & Wolverine," which made over $1.3 billion, or those of the 'Avengers'-era. But critically, the films have been on an upswing since the poorly reviewed 'Captain America: Brave New World,' which ultimately grossed $415 million worldwide. ' Thunderbolts," which jumpstarted the summer movie season, was better received critically but financially is capping out at just over $382 million globally. Like Deadpool and Wolverine, the Fantastic Four characters had been under the banner of 20th Century Fox for years. The studio produced two critically loathed, but decently profitable attempts in the mid-2000s with future Captain America Chris Evans as the Human Torch. In 2015, it tried again (unsuccessfully) with Michael B. Jordan and Miles Teller. They got another chance after Disney's $71 billion acquisition of Fox's entertainment assets in 2019. Top 10 movies by domestic box office With final domestic figures being released Monday, this list factors in the estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore: 1. 'The Fantastic Four: First Steps,' $118 million. 2. 'Superman,' $24.9 million. 3. 'Jurassic World Rebirth,' $13 million. 4. 'F1: The Movie,' $6.2 million. 5. 'Smurfs,' $5.4 million. 6. 'I Know What You Did Last Summer,' $5.1 million. 7. 'How to Train Your Dragon,' $2.8 million. 8. 'Eddington,' $1.7 million. 9. 'Saiyaara,' $1.3 million. 10. 'Oh, Hi!,' $1.1 million.


The Independent
9 hours ago
- The Independent
This fuzzy animal friend may be the key to treating schizophrenia
Llamas – likely without red pajamas – may hold the key to treating schizophrenia. The serious brain disorder causes people to interpret reality abnormally, and affects approximately 3.7 million U.S. adults between the ages of 18 to 65 years old, according to the nonprofit RTI International. But the domesticated South American woolly animal might be be able to help. French researchers said this week that they had used llama antibodies, or proteins that help to protect the immune system, to design a tiny fragment of an antibody known as a 'nanobody' that will trigger a neurotransmitter in the brain involved in regulating neural activity. Neurotransmitters are chemical molecules that carry messages or signals from one nerve cell to the next target cell, according to the Cleveland Clinic. No llamas were harmed in the study and researchers can identify nanobodies in a petri dish. In the past, llama antibodies have also proven effective in fighting Covid and other 'SARS-like' viruses. When scientists at the Institute of Functional Genomics injected the molecule into the veins or the muscles, it was able to break the blood-brain barrier and effectively reach brain receptors. The barrier is a a tightly locked layer of cells that defend your brain from harmful substances. Studying the impact of the nanobodies in two tests using mice, the researchers found that they corrected cognitive deficits that were observed. There was an improvement of cognitive function with just one shot, and a prolonged effect over one week. Clinical studies are now required to show that their findings could be a new avenue of treatment for schizophrenia. "In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia," molecular biologist Jean-Philippe Pin told Newsweek.. He was a co-author of the research which was published in the journal Nature. Pin said that medications currently given to schizophrenia patients "treat the symptoms well, but less the cognitive deficits." The cause of the chronic condition remains unknown, but the World Health Organization says it is thought that an interaction between genes and a range of environmental factors may be the reason. The exact prevalence of schizophrenia is difficult to measure. Some have tied cases in Canada to cannabis use. Although schizophrenia can occur at any age, people are typically diagnosed between the ages of 16 and 30. Symptoms vary from person to person. There is no cure, but it can be treated through antipsychotic medications, talk therapy, and self-management strategies, the National Alliance on Mental Illness says. The study's authors hope to add this strategy to the list. 'This research confirms the potential of nanobodies as a new therapeutic strategy for acting on the brain, with their use eventually being broadened to include the treatment of other neurological illnesses,' the institute said in a statement.